Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

OGI - Organigram Global Inc. So'nggi Yangiliklar | Finranks

Home

OGI

O

Organigram Global Inc. (OGI)

NMS – Real vaqt narxi. Valyuta: USD

1.31

0.00 (0.00%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

1.34

+0.03 (2.29%)

Bozordan keyin: Mar 27, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH

Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended that holders of common shares of Organigram ("Shareholders") vote FOR the ordinary resolution (the "Transaction Resolution") to approve the indirect acquisition of Sanity Group GmbH ("Sanity") at the Company's Annu.

Organigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting

Organigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that it has mailed and filed a management information circular (the “Circular”) and related materials (the “Meeting Materials”) for its annual and special meeting (the “Meeting”) of the holders of its common shares (the “Shareholders”) to be held on March 30, 2026. The Circular is available under Organigram's profile on SEDAR+ at ww.

Organigram Global Expands FAST™ Innovation Platform with SHRED Shotz, Leveraging SHRED Brand Equity

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1 is pleased to announce the launch of SHRED Shotz, a compact, single-serve 65ml cannabis beverage powered by FAST™, Organigram's fast-acting nanoemulsion technology platform designed to deliver a 15-minute onset2. This launch reflects Organigram's focus on differentiated innovation while leveraging the scale of SHRED, one of the Company's best-.

3 Canadian Marijuana Stocks To Diversify Your Stock Portfolio

3 Canadian Marijuana Stocks To Diversify Your Stock Portfolio

Marijuana stocks, even with their volatile behavior, still offer diverse investment opportunities. Not every sector or company deals directly with the plant, so investors see this as an opportunity to capitalize. Now, even with that said, MSO and companies that work directly with the plant tend to capture more market share. Also, they are usually the first to see a run in trading when the time comes.

Organigram Further Expands Global Portfolio with Launch of Edison and BOXHOT Medical Vapes and Pastilles in Australia

Organigram Further Expands Global Portfolio with Launch of Edison and BOXHOT Medical Vapes and Pastilles in Australia

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (“Organigram” or the “Company”) today announced the expansion of its international product portfolio, with the launch of Edison and BOXHOT medical cannabis vape and pastille products in Australia. Australia has become one of the world's most dynamic medical cannabis markets, with increasing approvals for access and prescribers utilising a broader range of dosage forms1. While flower remains a core category, alternatives such as vapes and pastille.

Organigram Announces C$65.2 Million BAT Private Placement Investment in Connection with the Acquisition of Sanity Group

Organigram Announces C$65.2 Million BAT Private Placement Investment in Connection with the Acquisition of Sanity Group

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading global cannabis company, today announced that it has entered into a subscription agreement (the “Subscription Agreement”) with BT DE Investments Inc. ( “BAT”), a wholly-owned subsidiary of British American Tobacco p.l.c. (LSE: BATs and NYSE: BTI), in connection with its previously announced proposed acquisition (the “Acquisition”) of Sanity Group GmbH (“Sanity” or “Sanity Group”.

Organigram Announces Proposed Acquisition of Sanity Group, a Leading German Cannabis Company

Organigram Announces Proposed Acquisition of Sanity Group, a Leading German Cannabis Company

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that it has entered into a definitive agreement (the “Purchase Agreement”) to acquire (the “Acquisition”) all the issued and outstanding shares of Sanity Group GmbH (“Sanity” or “Sanity Group”) not currently owned by Organigram. Upon closing of the Acquisition, Organigram will pay shareholders of Sanity (collectively, the “Ve.

Videolar

No Data

There is no data to display

Press-relizlar

Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH

Organigram Announces Independent Proxy Advisory Firm ISS Recommends Organigram Shareholders Vote FOR the Acquisition of Sanity Group GmbH

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended that holders of common shares of Organigram ("Shareholders") vote FOR the ordinary resolution (the "Transaction Resolution") to approve the indirect acquisition of Sanity Group GmbH ("Sanity") at the Company's Annu.

Organigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting

Organigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that it has mailed and filed a management information circular (the “Circular”) and related materials (the “Meeting Materials”) for its annual and special meeting (the “Meeting”) of the holders of its common shares (the “Shareholders”) to be held on March 30, 2026. The Circular is available under Organigram's profile on SEDAR+ at ww.

Organigram Global Expands FAST™ Innovation Platform with SHRED Shotz, Leveraging SHRED Brand Equity

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1 is pleased to announce the launch of SHRED Shotz, a compact, single-serve 65ml cannabis beverage powered by FAST™, Organigram's fast-acting nanoemulsion technology platform designed to deliver a 15-minute onset2. This launch reflects Organigram's focus on differentiated innovation while leveraging the scale of SHRED, one of the Company's best-.

Organigram Further Expands Global Portfolio with Launch of Edison and BOXHOT Medical Vapes and Pastilles in Australia

Organigram Further Expands Global Portfolio with Launch of Edison and BOXHOT Medical Vapes and Pastilles in Australia

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (“Organigram” or the “Company”) today announced the expansion of its international product portfolio, with the launch of Edison and BOXHOT medical cannabis vape and pastille products in Australia. Australia has become one of the world's most dynamic medical cannabis markets, with increasing approvals for access and prescribers utilising a broader range of dosage forms1. While flower remains a core category, alternatives such as vapes and pastille.